Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
LungLife AI Inc on Monday said its full-year loss widened, as administration expenses climbed.
LungLife is a California, US-based developer of clinical diagnostic solutions designed to aid the early detection of lung cancer.
Revenue in 2022 fell to $24,000 from $195,000 year-on-year.
LungLife AI pretax loss widened to $7.6 million in 2022 from $7.4 million a year ago. Earnings before interest, tax, depreciation and amortisation loss widened to $6.8 million from a loss of $5.4 million.
The company noted that administration expenses rose to $6.9 million from $5.5 million
Cash at December 31 amounted to $8.0 million, lower versus to $14.6 million on the same date a year ago.
Looking ahead, LungLife said its focus is on the conclusion of its clinical validation study and subsequent submission to the US Food & Drug Administration.
Chief Executive Officer Paul Pagano said: ‘We remain focused on completing our clinical validation study, commencing our clinical utility study later this year and expanding patient access to LungLB through implementation of our commercial reimbursement plan. We are very excited by the opportunities ahead and the potential for LungLB to transform the early detection of lung cancer.’
Shares in LungLife were up 0.5% to 100.50 pence each in London on Monday afternoon.
Copyright 2023 Alliance News Ltd. All Rights Reserved.